ABEA2025: Exclusive Interview Dr. Yu Hsiang Chang, Locus Cell

Locus Cell Named “Emerging CDMO of the Year” at ABEA2025
‍
ABEA 2025 Exclusive Interview with Dr. Yu Hsiang Chang, Locus Cell
📍 12 March 2025 | Singapore

Locus Cell has been honored as the “Emerging CDMO of the Year” at the Asia-Pacific Biopharma Excellence Awards 2025, a recognition of its rapid rise and impactful contributions to biologics and advanced therapy manufacturing in the region.

In an exclusive ABEA2025 interview, Dr. Yu Hsiang Chang, CEO of Locus Cell, joined Celine, Marketing Executive at IMAPAC, to share insights on the company’s journey, innovation strategy, and future vision as a next-generation CDMO.

Known for its cutting-edge bioprocessing technologies, strategic collaborations, and regulatory excellence, Locus Cell is driving progress in regenerative medicine and positioning itself as a key player in the Asia-Pacific biopharma landscape.

This award and exclusive conversation highlight the company’s growing influence—and its mission to deliver transformative therapies to patients worldwide.

‍